Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.
作者信息
Jimenez Javier, Gwillim Eran C, Kosche Cory, Figueiredo Anna, Rauck Corrine, Rangel Stephanie M, Choi Jennifer, West Dennis P, Nardone Beatrice, Lacouture Mario E
机构信息
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
出版信息
J Am Acad Dermatol. 2020 Sep;83(3):955-957. doi: 10.1016/j.jaad.2020.01.059. Epub 2020 Jan 31.
Abstract
摘要
相似文献
1
Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.与程序性死亡受体-1（PD-1）和程序性死亡配体-1（PD-L1）抑制剂相关的大疱性疾病：来自药物不良事件和报告项目研究的美国食品药品监督管理局不良事件报告系统的药物警戒分析
J Am Acad Dermatol. 2020 Sep;83(3):955-957. doi: 10.1016/j.jaad.2020.01.059. Epub 2020 Jan 31.
2
Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.免疫检查点抑制剂相关的血栓栓塞事件：来自食品和药物管理局不良事件报告系统（FAERS）数据库的真实世界研究数据。
Int Immunopharmacol. 2021 Sep;98:107818. doi: 10.1016/j.intimp.2021.107818. Epub 2021 Jun 12.
3
Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.免疫检查点抑制剂治疗相关的心律失常事件：基于食品和药物管理局不良事件报告系统数据库的真实世界研究。
Cancer Med. 2023 Mar;12(6):6637-6648. doi: 10.1002/cam4.5438. Epub 2022 Nov 24.
4
Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system.纳武利尤单抗联合二甲双胍治疗相关的炎症性肠病：来自 FDA 不良事件报告系统的数据。
Cancer Chemother Pharmacol. 2019 Mar;83(3):599-601. doi: 10.1007/s00280-018-03763-5. Epub 2019 Jan 8.
5
Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.免疫检查点抑制剂治疗患者的肠梗阻：使用食品和药物管理局不良事件报告系统数据库的回顾性药物警戒研究。
Pharmacoepidemiol Drug Saf. 2022 Nov;31(11):1199-1205. doi: 10.1002/pds.5493. Epub 2022 Jul 6.
6
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.免疫相关不良事件生成的影响老化由反程序死亡 (配体) PD-(L)1 疗法。
Eur J Cancer. 2020 Apr;129:71-79. doi: 10.1016/j.ejca.2020.01.013. Epub 2020 Mar 3.
7
Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.PD-1 抑制剂不良事件报告系统中与 PD-1 抑制剂相关的大疱性类天疱疮不良事件的比例分析。
Expert Opin Drug Saf. 2019 Jul;18(7):623-633. doi: 10.1080/14740338.2019.1619693. Epub 2019 May 22.
8
Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions.免疫检查点抑制剂联合质子泵抑制剂的不良反应：药物-药物相互作用的药物警戒分析。
BMC Cancer. 2024 Sep 27;24(1):1193. doi: 10.1186/s12885-024-12947-7.
9
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.程序性细胞死亡蛋白 1 与程序性细胞死亡配体 1 抑制剂在转移性肾细胞癌中的肿瘤学和毒性结局差异：系统评价和荟萃分析。
Cancer Treat Rev. 2021 Sep;99:102242. doi: 10.1016/j.ctrv.2021.102242. Epub 2021 Jun 12.
10
Hematologic Complications of Immune Checkpoint Inhibitors.免疫检查点抑制剂的血液学并发症。
Oncologist. 2019 May;24(5):584-588. doi: 10.1634/theoncologist.2018-0574. Epub 2019 Feb 28.
引用本文的文献
1
Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.扁平苔藓样天疱疮：一种继发于纳武利尤单抗的独特的水疱性和苔藓样发疹形式。
Dermatol Ther. 2022 May;35(5):e15432. doi: 10.1111/dth.15432. Epub 2022 Mar 15.
2
Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers.头颈部癌症靶向治疗和免疫治疗的皮肤毒性
Front Oncol. 2021 May 27;11:605941. doi: 10.3389/fonc.2021.605941. eCollection 2021.
3
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance.从免疫相关不良事件的真实世界研究中吸取的经验教训：药物警戒的临床视角。
Target Oncol. 2020 Aug;15(4):449-466. doi: 10.1007/s11523-020-00738-6.
本文引用的文献
1
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.抗 PD-1 和抗 PD-L1 治疗相关的大疱性疾病：一项回顾性分析，评估了临床和组织病理学特征、频率以及对癌症治疗的影响。
J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.
2
Data mining of the public version of the FDA Adverse Event Reporting System.对 FDA 不良事件报告系统公开版本的数据挖掘。
Int J Med Sci. 2013 Apr 25;10(7):796-803. doi: 10.7150/ijms.6048. Print 2013.
3
Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.研究药物不良反应和报告（RADAR）项目开展的第一个十年的研究结果。
Drug Saf. 2013 May;36(5):335-47. doi: 10.1007/s40264-013-0042-x.
Zotero 插件